Comparative Pharmacology
Head-to-head clinical analysis: CARIPRAZINE HYDROCHLORIDE versus LATUDA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARIPRAZINE HYDROCHLORIDE versus LATUDA.
CARIPRAZINE HYDROCHLORIDE vs LATUDA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cariprazine is a partial agonist at dopamine D3 and D2 receptors, with higher affinity for D3 receptors, and a partial agonist at serotonin 5-HT1A receptors; it is an antagonist at 5-HT2A and 5-HT2B receptors.
Lurasidone is an atypical antipsychotic with high affinity for dopamine D2, serotonin 5-HT2A, and serotonin 5-HT7 receptors, and moderate affinity for serotonin 5-HT1A receptors. It acts as an antagonist at D2 and 5-HT2A receptors, and as a partial agonist at 5-HT1A receptors. The exact mechanism of action in schizophrenia and bipolar depression is unknown but is thought to involve modulation of these receptors.
1.5 mg orally once daily, with a recommended titration starting at 1.5 mg on day 1, increased to 3 mg on day 2, then 4.5 mg on day 3, and 6 mg on day 4; target dose range: 1.5–6 mg once daily, with a maximum of 6 mg/day.
40 mg orally once daily initially, titrated to 80-160 mg once daily; maximum 160 mg/day. Administer with food (at least 350 calories).
None Documented
None Documented
Terminal elimination half-life: 2–5 days (48–120 hours) for cariprazine and its major active metabolites (desmethylcariprazine, didesmethylcariprazine). The long half-life supports once-daily dosing and allows for gradual dose titration.
Terminal elimination half-life is approximately 20–40 hours (mean about 29 hours) in adults, supporting once-daily dosing. Steady-state is reached within 7 days.
Primarily hepatic metabolism via CYP3A4 and CYP2D6, with 60% excreted in feces (mostly as metabolites) and 30% in urine (mostly as metabolites). Less than 1% excreted unchanged.
Approximately 80% of the dose is eliminated in feces (mostly as unchanged drug and metabolites) and about 10% in urine. Less than 2% is excreted as unchanged lurasidone in urine.
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic